Improving Exposure Therapy: Rationale and Design of an International Consortium.

The Exposure Therapy Consortium (ETC) was established to advance the science and practice of exposure therapy. To encourage participation from researchers and clinicians, this article describes the organizational structure and activities of the ETC. Initial research working group experiences and a proof-of-principle study underscore the potential of team science and larger-scale collaborative research in this area. Clinical working groups have begun to identify opportunities to enhance access to helpful resources for implementing exposure therapy effectively. This article discusses directions for expanding the consortium's activities and its impact on a global scale.
Competing Interests: Disclosure Funding Support: Author effort was supported as follows: Dr J.A.J. Smits (NIMHR01MH125951), Dr S.G. Hofmann (Alexander von Humboldt Foundation, Germany and Hessische Ministerium für Wissenschaft und Kunst), Dr J. Newby (NHMRC2008839), Australia, and Dr M.W. Otto (NIMH R01 MH125949), United States. These funding sources had no role in the content or the decision to publish this article.Dr J.A.J. Smits receives funding from National Institute on Drug Abuse (NIDA R01DA047933), United States, the National Cancer Institute (NCI R01CA273221), United States, and Department of Defense (TP220002), United States, and compensation and royalties from various publishers. Dr J.J. Arch receives current research funding from the National Institutes of Health, United States/National Institute of Nursing Research (R01NR018479). Dr S G. Hofmann receives financial support by the Alexander von Humboldt Foundation (as part of the Alexander von Humboldt Professur) and the Hessische Ministerium für Wissenschaft und Kunst (as part of the LOEWE Spitzenprofessur). He also receives compensation for his work as editor from SpringerNature and royalties and payments for his work from various publishers. Dr P.M. McEvoy receives compensation from The Guilford Press, Elsevier, Cambridge University Press, and McGraw-Hill Education. Dr J. Newby receives funding from the Australian National Medical Research Council, and the Medical Research Future Fund. Dr M.W. Otto receives compensation as an advisor to Big Health and receives grant support from National Institute of Mental Health, United States, NIDA, and Big Health. Dr D. Rosenfield reports funding from NIMH, NCI, National Center for Complementary and Integrative Health, United States, and the Patient-Centered Outcomes Research Institute, United States. He also receives compensation from several scientific journals and from Rosenfield Analytics. Dr W.Rief received honoraria from Boehringer Ingelheim for talks on Post Covid, and he receives royalties from book publications from different publishers. All other authors report no conflicts of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)